Results of the April 2015 Innovation to Impact Grants competition

We are pleased to announce the results of the most recent Innovation to Impact Grants competition to support the further development of successful findings based on the goals originally explored through a CCSRI Innovation Grant. Below is a listing of newly awarded Canadian Cancer Society (CCS) Innovation to Impact Grants.

Out of a total of 14 grant applications, 6 Canadian Cancer Society Innovation to Impact Grants have been approved – a 43% success rate. All grants have been awarded to a maximum budget of $450,000 with a maximum 3 year term. The 6 grants total over $2.6 million in funding over the terms of these grants.

We are also very pleased that all grants are being funded to their full panel recommended amounts and that no administrative decrements are being applied.

Funds committed to this competition have been made possible by the significant efforts of Canadian Cancer Society volunteers and donors across the country.

Summaries of awarded grants

Please note:
  • Amounts listed below represent the total dollars awarded by grant year and may include funds for salaries, supplies, and/or equipment.
  • The start date for these grants is August 1, 2015.
  • Only the Principal Investigator is named in this listing. Co-Principal Investigators, Co-Applicants and/or Additional Authors may also be associated with these grants.
Note Carefully:

Although every effort has been made to ensure the accuracy of the listing below, this list does not constitute an "official" notification.

Successful applicants will be informed, in writing, with an official Notification of Award giving the details pertaining to their grant.

Broady, Raewyn
University of British Columbia
Expansion of human antigen-specific T regulatory cells to prevent graft-versus-host disease (GVHD)
2015/2016 :  $150,000
2016/2017 :  $150,000
2017/2018 :  $150,000
Gunning, Patrick
University of Toronto
Investigating the UBA5 enzyme in cancer proliferation and as a promising target for adjuvant therapy
2015/2016 :  $149,999
2016/2017 :  $149,999
2017/2018 :  $150,000
Khokha, Rama
Ontario Cancer Institute/PMCC - UHN
Novel genetic targets in breast cancer subtypes via Lentihop mutagenesis
2015/2016 :  $150,000
2016/2017 :  $150,000
2017/2018 :  $150,000
Makrigiannis, Andrew
University of Ottawa
Innate immune evasion by the cancers of the blood and breast
2015/2016 :  $148,071
2016/2017 :  $150,000
2017/2018 :  $150,000
Porter, Lisa
University of Windsor
Role of Spy1 in driving brain tumour initiating cells
2015/2016 :  $150,000
2016/2017 :  $150,000
2017/2018 :  $128,896
Stagljar, Igor
University of Toronto
Functional analysis of the EGFR interactome and its role in non–small cell lung cancer
2015/2016 :  $150,000
2016/2017 :  $150,000
2017/2018 :  $150,000

Last modified on: December 2, 2019